Properties (56)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biotechnology company
|
| gptkbp:acquisition |
Provenance Biopharmaceuticals
|
| gptkbp:CEO |
gptkb:Yvonne_Greenstreet
|
| gptkbp:clinicalTrials |
gptkb:Asia
gptkb:Australia gptkb:North_America gptkb:South_America Europe Phase 1 Phase 2 Phase 3 collaborative studies post-marketing studies preclinical studies |
| gptkbp:collaborations |
gptkb:University_of_Massachusetts_Medical_School
gptkb:Harvard_University gptkb:MIT |
| gptkbp:employees |
~800 (2021)
|
| gptkbp:focus |
RNA interference
|
| gptkbp:founded |
2002
|
| gptkbp:founder |
gptkb:John_Maraganore
|
| gptkbp:funding |
$1 billion (2021)
|
| gptkbp:headquarters |
gptkb:Cambridge,_Massachusetts
|
| https://www.w3.org/2000/01/rdf-schema#label |
Alnylam Pharmaceuticals
|
| gptkbp:investmentFocus |
Institutional Investors
Public Investors Venture_Capital |
| gptkbp:leadership |
Executive Team
Board_of_Directors |
| gptkbp:market |
$10 billion (2021)
|
| gptkbp:notableEvent |
Developed therapies for acute hepatic porphyria
Developed therapies for hypercholesterolemia Developed therapies for transthyretin amyloidosis First RNAi therapeutic approved by FDA Developed therapies for hereditary ATTR amyloidosis |
| gptkbp:partnerships |
gptkb:Regeneron_Pharmaceuticals
Sanofi |
| gptkbp:patentCitation |
RNAi technology
drug delivery systems therapeutic applications |
| gptkbp:products |
gptkb:Onpattro
gptkb:Givlaari Leqvio |
| gptkbp:regulatoryCompliance |
gptkb:FDA
EMA PMDA |
| gptkbp:research_areas |
rare diseases
cardiovascular diseases infectious diseases neurological diseases metabolic diseases |
| gptkbp:researchFocus |
genetic diseases
|
| gptkbp:revenue |
$300 million (2020)
|
| gptkbp:stockSymbol |
gptkb:ALNY
|
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:website |
www.alnylam.com
|